Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Treatment

Active surveillance of prostate cancer

Oncologic Therapy

Active surveillance is a management option for men with localized, low risk prostate cancer who could also choose immediate surgery or radiation but instead have their cancer monitored, with treatment given only if the disease shows signs of progressing. It differs from watchful waiting, which is reserved for men who are no longer candidates for curative treatment because of limited life expectancy, since active surveillance keeps that option open. The approach exists because many localized prostate cancers, especially in older men, grow slowly enough that aggressive treatment and its side effects, including urinary, sexual, and bowel dysfunction, can do more harm than the cancer itself, yet an estimated 100,000 American men who qualify for active surveillance each year still undergo unnecessary treatment.

Facts
Classification
Status
Standard of Care 1
Connections

Treats

Source Active surveillance of prostate cancer (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Active_surveillance_of_prostate_cancer, lead section
Quote, https://en.wikipedia.org/wiki/Active_surveillance_of_prostate_cancer, lead section
Active surveillance is a management option for localized prostate cancer that can be offered to appropriate patients who would also be candidates for aggressive local therapies, with the intent to intervene if the disease progresses.
View the Source
Active surveillance of prostate cancer (Wikipedia)
Treats: Prostate Cancer, Lead: treats Prostate Cancer
Quote, Treats: Prostate Cancer, Lead: treats Prostate Cancer
In the meantime, active surveillance for the treatment of low risk prostate cancer is now being offered to more and more patients where it is generally considered that prostate cancer will not cause the man harm during his lifetime if treatment is delayed or avoided.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.